MiNK data published showing complete remission, says H.C. Wainwright

MiNK Therapeutics (INKT) on Friday announced publication in Nature’s Oncogene of a case of a patient treated with a single dose of agenT-797 + nivolumab who had complete remission which has been durable with no evidence of disease over two years later, H.C. Wainwright tells investors in a research note. The response was a complete clinical, radiologic, and biochemical remission, with donor iNKT cells detectable for up to 6 months post-infusion, the firm says. H.C. Wainwright has a Buy rating and $35 price target ont he shares.